Eli Lilly and Company

• LLY Stock Price 24h change: -3.63%. From 1073.29 USD to 1034.33 USD.
• Technical analysis indicates a short-term bearish correction within a long-term bullish trend. The price is currently testing key support at the $1,030 - $1,036 level, with the RSI at 48.7 showing neutral momentum and the MACD reflecting a cautious bearish crossover despite remaining above long-term moving averages.
• Eli Lilly is showcasing its late-stage pipeline, including the obesity pill orforglipron and the triple-agonist retatrutide, at the J.P. Morgan Healthcare Conference (Jan 12-14, 2026), aiming to maintain its dominance in the GLP-1 market.
• Analysts maintain a "Buy" consensus with price targets reaching $1,250 for 2026, citing 53.9% YoY revenue growth driven by record Zepbound and Mounjaro sales, though high valuation (Forward P/E ~32x) remains a point of debate.
• The biopharma sector faces "unpredictable risk" in 2026 due to leadership turnover at the FDA and policy uncertainty regarding drug price reforms, which may drive M&A interest toward advanced-stage clinical programs.
• Global drugmakers are bracing for a pricing battle in Europe as they seek higher reimbursement rates to offset U.S. price-cut agreements reached under political pressure, potentially delaying new drug launches in EU markets.

• LLY Stock Price 24h change: -0.35%. From 1,081.00 USD to 1,077.19 USD. (January 13, 2026)
• From a technical perspective, LLY shows a "bullish consolidation" pattern: while the long-term trend is supported by a rising 200-day SMA ($865.79), short-term momentum is cooling with a 14-day RSI of 44.97, suggesting a neutral to slight downward bias as the market digests recent gains.
• Eli Lilly and NVIDIA announced a $1 billion co-innovation lab on January 12, 2026, to utilize AI for drug discovery and digital twin manufacturing.
• On January 7, 2026, Lilly acquired Ventyx Biosciences for $1.2 billion to bolster its oral immunology pipeline and counter competition from Novo Nordisk's oral obesity treatments.
• CEO David Ricks stated at the JPM Healthcare Conference that the company expects a second-quarter 2026 FDA decision on its highly anticipated oral obesity medication.
• AbbVie pledged $100 billion to U.S. production and research on January 13, 2026, as part of a strategic drug-pricing agreement with the U.S. administration.
• Novo Nordisk launched its nationwide rollout of the Wegovy oral weight-loss pill in early January 2026, intensifying competition in the GLP-1 market.